

06 November 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Director/PDMR Dealing

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 172,460 ordinary shares of 2.5 pence each in the capital of the Company at a price of 23.2p per share ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the existing Ordinary Shares and were issued following the exercise of options by Jim Mellon and Dr Greg Bailey, non-executive Directors of the Company. The gross proceeds of the exercise amounting to £40,010.72 were set off against amounts owing by the Company to Messrs Mellon and Bailey.

The options were exercised pursuant to the Rule 9 Waiver detailed in the Company's AIM admission document dated 3 March 2016. Following the issue of the New Ordinary Shares, the interests of Messrs Mellon and Bailey in the issued share capital of the Company are as follows:

Optionholder	Options exercised	Resultant interest in Ordinary Shares	% of enlarged share capital
Jim Mellon	86,230	13,406,521	36.53
Dr Greg Bailey	86,230	13,406,521	36.53

The interest of Jim Mellon in the above table includes interests held through Galloway Limited and Port Erin Biopharma Investments Limited.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 9 November 2018.

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued ordinary share capital will comprise 36,699,642 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. This figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

This announcement contains inside information.

Enquiries

SalvaRx Group plc

Ian B. Walters, MD (Chief Executive)

Tel: +1 203 441 5451

Nominated Adviser and Broker

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

The information below is set out in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	James Mellon				
2	Reason for the notification					
a)	Position/status	Director				
b)	Initial notification /Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	SalvaRx Group plc				
b)	LEI	213800G2OYVF7NTWRF98				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 2.5p each IM00BZ4SS228				
b)	Nature of the transaction	Exercise of options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>23.2p</td> <td>86,230</td> </tr> </tbody> </table>	Price(s)	Volume(s)	23.2p	86,230
Price(s)	Volume(s)					
23.2p	86,230					
d)	Aggregated information - Aggregated volume - Price	 86,230 23.2p				
e)	Date of the transaction	31 October 2018				

f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Gregory Bailey				
2	Reason for the notification					
a)	Position/status	Director				
b)	Initial notification /Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	SalvaRx Group plc				
b)	LEI	213800G2OYVF7NTWRF98				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 2.5p each IM00BZ4SS228				
b)	Nature of the transaction	Exercise of options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>23.2p</td> <td>86,230</td> </tr> </tbody> </table>	Price(s)	Volume(s)	23.2p	86,230
Price(s)	Volume(s)					
23.2p	86,230					
d)	Aggregated information - Aggregated volume - Price	 86,230 23.2p				
e)	Date of the transaction	31 October 2018				
f)	Place of the transaction	Outside a trading venue				

